Rosacea Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$2000

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Rosacea – Drugs In Development, 2022, provides an overview of the Rosacea (Dermatology) pipeline landscape.

Rosacea is a chronic and potentially life-disruptive disorder primarily of the facial skin, often characterized by flare-ups and remissions. Symptoms include frequent redness of the face, or flushing, small, red lines under the skin, a swollen nose and thick skin, usually on the forehead, chin, and cheeks. The predisposing factors include age and family history of rosacea. Treatment includes antibiotics and acne drugs.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Rosacea – Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Rosacea (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Rosacea (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Rosacea and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II and Preclinical stages are 2, 11 and 13 respectively.

Rosacea (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

* Global Markets Direct, is a research brand owned and operated by GlobalData.

Scope

– The pipeline guide provides a snapshot of the global therapeutic landscape of Rosacea (Dermatology).

– The pipeline guide reviews pipeline therapeutics for Rosacea (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

– The pipeline guide reviews key companies involved in Rosacea (Dermatology) therapeutics and enlists all their major and minor projects.

– The pipeline guide evaluates Rosacea (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

– The pipeline guide reviews latest news related to pipeline therapeutics for Rosacea (Dermatology)

Reasons to Buy

– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

– Find and recognize significant and varied types of therapeutics under development for Rosacea (Dermatology).

– Classify potential new clients or partners in the target demographic.

– Develop tactical initiatives by understanding the focus areas of leading companies.

– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

– Formulate corrective measures for pipeline projects by understanding Rosacea (Dermatology) pipeline depth and focus of Indication therapeutics.

– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Accuitis Pharmaceuticals Inc
Alfasigma SpA
Amgen Inc
Amytrx Therapeutics Inc
AOBiome LLC
Arcutis Biotherapeutics Inc
Attillaps Holdings Inc
Biomimetix JV LLC
Botanix Pharmaceuticals Ltd
Cellix Bio Pvt Ltd
Dermata Therapeutics Inc
Evommune Inc
Hovione FarmaCiencia SA
Maruho Co Ltd
Matrisys Bioscience Inc
NanoPharmaceuticals LLC
Perpetuum BV
Promius Pharma LLC
Retinoids JSC
Sunny Pharmtech Inc
Tarsus Pharmaceuticals Inc
Timber Pharmaceuticals Inc
TWi Biotechnology Inc
VYNE Therapeutics Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Rosacea – Overview

Rosacea – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Rosacea – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Rosacea – Companies Involved in Therapeutics Development

Rosacea – Drug Profiles

Rosacea – Dormant Projects

Rosacea – Discontinued Products

Rosacea – Product Development Milestones

Featured News & Press Releases

Jun 13, 2022: Dermata announces final patient enrolled in a phase 2 trial of DMT310 for the once-weekly treatment of moderate-to-severe rosacea

Mar 17, 2022: Journey Medical Corporation announces first patient dosed in phase 3 clinical trial evaluating DFD-29 (minocycline modified release capsules 40 mg) for the treatment of rosacea

Nov 17, 2021: Dermata announces first patient enrolled in its phase 2 trial of DMT310 for the treatment of moderate-to-severe rosacea

Sep 20, 2019: Hovione announces successful end-of-phase 2 meeting with the FDA and outlines phase 3 program for minocycline topical gel

Jun 26, 2019: BioPharmX reports positive results from BPX-041 trial for rosacea

May 22, 2019: BioPharmX announces last patient visit in Phase 2b trial of BPX-04 for papulopustular rosacea

Mar 04, 2019: BioPharmX completes enrollment in phase 2b trial of BPX-04 for patients with papulopustular rosacea

Oct 12, 2018: BioPharmX enrols first subject in Phase llb trial of BPX-04

Aug 01, 2018: BioPharmX secures IRB approval to start Phase ll trial of BPX-04

May 24, 2018: BioPharmX Studies Show Hydrophilic Topical Minocycline Gel May Be the Preferred Treatment Option for Rosacea Patients

Mar 20, 2018: U.S. Patent and Trademark Office Awards BioPharmX Patent Protection for Novel Tetracycline-class Topical Drug BPX-04

Jan 26, 2018: BioPharmX To Present Data On New Fluorescence Lifetime Imaging Microscopy to Measure How Effectively Topically Applied Minocycline Reaches Targets in Skin

Jan 12, 2018: BioPharmX to Present BPX-04 Rosacea Data at Two Leading Clinical Conferences This Month

Dec 13, 2017: Hovione Announces Enrollment of First Patient in MARS, a Phase 2 Clinical Trial for the Treatment of Moderate to Severe Inflammatory Rosacea with its Proprietary Minocycline Topical Gel

Sep 12, 2017: BioPharmX Announces Preliminary Data from Rosacea Feasibility Study

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Products under Development for Rosacea, 2022

Number of Products under Development by Companies, 2022

Products under Development by Companies, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Rosacea – Pipeline by Accuitis Pharmaceuticals Inc, 2022

Rosacea – Pipeline by Alfasigma SpA, 2022

Rosacea – Pipeline by Amgen Inc, 2022

Rosacea – Pipeline by Amytrx Therapeutics Inc, 2022

Rosacea – Pipeline by AOBiome LLC, 2022

Rosacea – Pipeline by Arcutis Biotherapeutics Inc, 2022

Rosacea – Pipeline by Attillaps Holdings Inc, 2022

Rosacea – Pipeline by Biomimetix JV LLC, 2022

Rosacea – Pipeline by Botanix Pharmaceuticals Ltd, 2022

Rosacea – Pipeline by Cellix Bio Pvt Ltd, 2022

Rosacea – Pipeline by Dermata Therapeutics Inc, 2022

Rosacea – Pipeline by Evommune Inc, 2022

Rosacea – Pipeline by Hovione FarmaCiencia SA, 2022

Rosacea – Pipeline by Maruho Co Ltd, 2022

Rosacea – Pipeline by Matrisys Bioscience Inc, 2022

Rosacea – Pipeline by NanoPharmaceuticals LLC, 2022

Rosacea – Pipeline by Perpetuum BV, 2022

Rosacea – Pipeline by Promius Pharma LLC, 2022

Rosacea – Pipeline by Retinoids JSC, 2022

Rosacea – Pipeline by Sunny Pharmtech Inc, 2022

Rosacea – Pipeline by Tarsus Pharmaceuticals Inc, 2022

Rosacea – Pipeline by Timber Pharmaceuticals Inc, 2022

Rosacea – Pipeline by TWi Biotechnology Inc, 2022

Rosacea – Pipeline by VYNE Therapeutics Inc, 2022

Rosacea – Dormant Projects, 2022

Rosacea – Dormant Projects, 2022 (Contd..1)

Rosacea – Discontinued Products, 2022

Figures

List of Figures

Number of Products under Development for Rosacea, 2022

Number of Products under Development by Companies, 2022

Number of Products by Targets, 2022

Number of Products by Stage and Targets, 2022

Number of Products by Mechanism of Actions, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Molecule Types, 2022

Frequently asked questions

Rosacea Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update thematic reports
Currency USD
$2,000

Can be used by individual purchaser only

$6,000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Rosacea Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Rosacea Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.